Loading clinical trials...

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGPhase 2NCT06794996

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).

Lead sponsor: Vertex Pharmaceuticals Incorporated•35 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Medical Information

CONTACT

617-341-6777 medicalinfo@vrtx.com

Related studies

RECRUITINGPhase 2

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296 · Proteinuric Kidney Diseases

Not Yet RecruitingPhase 1

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

NCT07224776 · Proteinuric Renal Disease, Proteinuric Kidney Disease, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 8, 2026Terms

Trial snapshot

StatusRECRUITING

PhasePHASE2

Enrollment45

Start dateFeb 2025

Last updatedApr 8, 2026

Condition

Proteinuric Kidney Disease

Locations shown

Nephrology Consultants, LLC

Huntsville, Alabama

Foundation for Sickle Cell Disease Research, LLC

Hollywood, Florida

South Florida Research Institute

Lauderdale Lakes, Florida

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 8, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions